vimarsana.com
Home
Live Updates
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis : vimarsana.com
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032
On track to share interim Phase 1b data in H1 2024
...
Related Keywords
United States ,
Japan ,
California ,
San Diego ,
China ,
Joseph Payne ,
Linkedin ,
Arcturus Therapeutics Holdings Inc ,
Twitter ,
Office Of Orphan Products Development ,
Nasdaq ,
Mrna Technology ,
Drug Designation For The Company ,
Drug Administration ,
Arcturus Therapeutics Holdings ,
Orphan Drug Designation ,
Orphan Products Development ,
Prescription Drug User Fee Act Application ,
Drug Designation ,
Chief Executive Officer ,
Private Securities Litigation Reform Act ,
Annual Report ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.